Search Results for "Pharmexec Top 50 2012"
Original Source: Novartis is again second in PharmExec’s 2012 ranking of the top 50 pharma companies based on Rx sales.
This year's Pharm Exec 50 shows an industry whose growth has slowed to a crawl in the face of patent expirations, aggressive payers, and a tough environment for approvals.
Matching Channels
Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...
ATX-MS-1467 for patients with multiple sclerosis (MS)
ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the...
According to the American Brain Tumor Association, just over 24,000 patients will be diagnosed with a primary malignant brain tumour during 2012 in the US alone. Some 80% of primary malignant brain...
Coronavirus were first identified in the 1960s, and were named after the crown-like projections on the surface of the virus. They cause respiratory infections in both humans and animals. Coronavir...
Sequencing platforms in diagnostic laboratories may aid both patient management by detecting resistance associated mutations, and public health measures, by determining phylogenetic relationships be...
Matching News
This year's Pharm Exec 50 shows an industry whose growth has slowed to a crawl in the face of patent expirations, aggressive payers, and a tough environment for approvals.
This year's Pharm Exec 50 shows an industry whose growth has slowed to a crawl in the face of patent expirations, aggressive payers, and a tough environment for approvals.
NEW YORK, March 26, 2013 /PRNewswire/ -- Pharmaceutical Executive, the monthly magazine and daily online publication of record on analytics, trends and personalities in the biopharmaceutical indu...
NEW YORK, May 1, 2013 /PRNewswire/ -- PHARMACEUTICAL EXECUTIVE magazine's April cover story profiles Bridgette P. Heller, executive vice president at Merck, president of Merck Consumer Care...
Comment on Emerging Countries' R&D: A Contest, but No Wipe Out by DrPolicy
After reading this I had to ask; is it just me or does it seem that the policies of western nations, led by the U.S., seem to be moving in the opposite direction of growing BRICK nations when it comes...
Singapore GDP grew more than expected in Q4
* Q4 GDP +3.3 pct q/q vs median forecast of +2.1 pct * Q4 GDP +1.5 pct y/y vs median forecast of +1.2 pct * Full-year 2012 GDP +1.3 percent * Singapore reiterates 2013 growth forecast of 1...
NEW YORK, Feb. 21, 2013 /PRNewswire/ -- Biopharmaceuticals – the major source of new medicines and a key knowledge industry for the future – faces another rough year from empowered pa...
ALK-Abelló: Release date of nine-month interim report (Q3) 2012 for ALK
Copenhagen, 2012-10-29 16:13 CET (GLOBE NEWSWIRE) -- On Monday 12 November 2012, ALK releases its interim report for the nine months ended 30 September 2012. ALK will hold a conference call for ana...
Matching PubMed Articles
Nefrologia 2012;32(6):838-9. doi: 10.3265/Nefrologia.pre2012.Oct.11783. Reply to: Del Pozo et al. Comment on Nefrologia 2012;32(6):837. Nefrologia 2012; 32(4):419-26.
ISS/SIC Donations January 2012 Through June 2012.
Nefrologia 2012;32(6):835-7. doi: 10.3265/Nefrologia.pre2012.Oct.11731. Reply to: Serra Tarragon. Comment on Nefrologia 2012;32(6):835. Nefrologia 2012; 32(4):419-26.
Abstracts of the 2012 Vascular Annual Meeting. National Harbor, Maryland, USA. June 7-9, 2012.
